资源描述
单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Company Confidential,2011 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Company Confidential,2011 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,DIA-2-20121205-331,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,DIA-2-20121205-331,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,DIA-2-20121205-331,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Company Confidential,2011 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Company Confidential,2011 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,DIA-2-20121205-331,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,DIA-2-20121205-331,Lilly Diabetes,Company Confidential,2012 Eli Lilly and Company,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,DIA-2-20121205-331,单击此处编辑母版标题样式,*,单击此处编辑母版文本样式,第二级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,*,糖尿病的流行病学,DIA-3-20121205-331,1,PPT课件,糖尿病的流行病学DIA-3-20121205-3311PPT,2011,世界范围内糖尿病的患病率,成人患病率为,8.3%,并且这一数字仍在上升,2,欧洲,3,2011:5280,万,2030:6420,万,中东及北非,3,2011:3260,万,2030:5970,万,东南亚,3,2011:7140,万,2030:1.2,亿,南美及中美,3,2011:2510,万,2030:3990,万,非洲,3,2011:14.7 million,2030:28.0 million,西太平洋,3,2011:1,亿,3190,万,2030:1,亿,8790,万,到,2030,年估计全球糖尿病患病率为,9.9%,1,北美,3,2011:3770,万,2030:5120,万,1.IDF.http:/www.idf.org/diabetesatlas/5e/foreword.Accessed 18/03/2012.2.IDF.http:/www.idf.org/diabetesatlas/5e/diabetes.Accessed 18/03/2012.,3.IDF.http:/www.idf.org/diabetesatlas/5e/regional-overviews.Accessed 18/03/2012.,2,PPT课件,2011 世界范围内糖尿病的患病率成人患病率为8.3%并,2011,世界范围内糖耐量减低,(IGT),的患病率：,6.4%,且这一数字正在上升,1,1.IDF.http:/www.idf.org/diabetesatlas/5e/impaired-glucose-tolerance.Accessed 18/03/2012.2:IDF.http:/www.idf.org/diabetesatlas/5e/africa.Accessed 18/03/2012.,3.IDF.http:/www.idf.org/diabetesatlas/5e/europe.Accessed 18/03/2012.4.IDF.http:/www.idf.org/diabetesatlas/5e/middle-east-and-north-africa.Accessed 18/03/2012.,5.IDF.http:/www.idf.org/diabetesatlas/5e/north-america-and-caribbean.Accessed 18/03/2012.6.IDF.http:/www.idf.org/diabetesatlas/5e/south-and-central-america.Accessed 18/03/2012.,7.IDF.http:/www.idf.org/diabetesatlas/5e/south-east-asia.Accessed 18/03/2012.8.IDF.http:/www.idf.org/diabetesatlas/5e/western-pacific.Accessed 18/03/2012.,北美,5,2011:3690,万,2030:4720,万,中东及北非,4,2011:2390,万,2030:4100,万,东南亚,7,2011:2380,万,2030:3860,万,南美及中美,6,2011:1510,万,2030:2260,万,非洲,2,2011:3280,万,2030:6320,万,西太平洋,8,2011:8490,万,2030:1,亿,1410,万,到,2030,年全球,IGT,的患病率估计为,7.1%.,1,欧洲,3,2011:6300,万,2030:7150,万,3,PPT课件,2011 世界范围内糖耐量减低(IGT)的患病率：6.4%,患病率,(%),中国糖尿病患病率跃居世界第一,Diabetes Atlas,Fourth edition International Diabetes Federation,2009;,中华医学会糖尿病学分会,.,中华内分泌代谢杂志,2008;24:2a:1-22.,Yang WY,et al.N Engl J Med 2010;362:1090-1101.;2010,中国,2,型糖尿病治疗指南,:p12,downloaded from http:/www.cdschina.org/x_uploadfiles/dm201otaolungao.pdf,4,PPT课件,患病率(%)中国糖尿病患病率跃居世界第一Diabetes,中国糖耐量减低,(IGT),的患病率,1.2010,中国,2,型糖尿病治疗指南,:p1;2.,吴建华等,.,中国慢性病预防与控制,2007;15(1):76-77.;,3.,王克安等,.,中华流行病学杂志,1998;19(5):282-285.4.Diabetes Atlas,Fifrth edition International Diabetes Federation,2011.,5,PPT课件,中国糖耐量减低(IGT)的患病率1.2010中国2型糖尿病,糖尿病的类型,6,PPT课件,糖尿病的类型6PPT课件,主要的糖尿病类型,1,型糖尿病,5-10%,其他类型,2,型糖尿病,90-95%,妊娠期,糖尿病,(GDM),美国糖尿病协会,.Diabetes Care 2005;28(Suppl 1):S37-S42.,7,PPT课件,主要的糖尿病类型1型糖尿病其他类
展开阅读全文